Clinical Trial Update: The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab for efficacy and safety in refractory CIDP patients with IgG4 autoantibodies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Nagoya University | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Status: COMPLETED